Five years after the clinical trial ended, the beneficial effects of the AREDS formulation persisted for development of neovascularization (wet macular degeneration) but not for geographic atrophy (dry macular degeneration). These results are consistent with the original recommendations that persons with intermediate or advanced AMD in 1 eye should consider taking the AREDS formulation.
Friday, April 12, 2013
This AREDS report published in Ophthalmology updates us on the long-term (10 years) effects of vitamins C and E, Beta Carotene, and Zinc on macular degeneration. It concludes:
Posted by Dr. Kevin on April 12, 2013